• Je něco špatně v tomto záznamu ?

Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria

T. Majtan, H. Hůlková, I. Park, J. Krijt, V. Kožich, EM. Bublil, JP. Kraus,

. 2017 ; 31 (12) : 5495-5506. [pub] 20170816

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016415

Classical homocystinuria (HCU) is an inborn error of sulfur amino acid metabolism caused by deficient activity of cystathionine β-synthase (CBS), resulting in an accumulation of homocysteine and a concomitant decrease of cystathionine and cysteine in blood and tissues. In mice, the complete lack of CBS is neonatally lethal. In this study, newborn CBS-knockout (KO) mice were treated with recombinant polyethyleneglycolylated human truncated CBS (PEG-CBS). Full survival of the treated KO mice, along with a positive impact on metabolite levels in plasma, liver, brain, and kidneys, was observed. The PEG-CBS treatment prevented an otherwise fatal liver disease characterized by steatosis, death of hepatocytes, and ultrastructural abnormalities of endoplasmic reticulum and mitochondria. Furthermore, treatment of the KO mice for 5 mo maintained the plasma metabolite balance and completely prevented osteoporosis and changes in body composition that characterize both the KO model and human patients. These findings argue that early treatment of patients with HCU with PEG-CBS may prevent clinical symptoms of the disease possibly without the need of dietary protein restriction.-Majtan, T., Hůlková, H., Park, I., Krijt, J., Kožich, V., Bublil, E. M., Kraus, J. P. Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016415
003      
CZ-PrNML
005      
20180518090928.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1096/fj.201700565R $2 doi
035    __
$a (PubMed)28821635
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Majtan, Tomas $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA; tomas.majtan@ucdenver.edu.
245    10
$a Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria / $c T. Majtan, H. Hůlková, I. Park, J. Krijt, V. Kožich, EM. Bublil, JP. Kraus,
520    9_
$a Classical homocystinuria (HCU) is an inborn error of sulfur amino acid metabolism caused by deficient activity of cystathionine β-synthase (CBS), resulting in an accumulation of homocysteine and a concomitant decrease of cystathionine and cysteine in blood and tissues. In mice, the complete lack of CBS is neonatally lethal. In this study, newborn CBS-knockout (KO) mice were treated with recombinant polyethyleneglycolylated human truncated CBS (PEG-CBS). Full survival of the treated KO mice, along with a positive impact on metabolite levels in plasma, liver, brain, and kidneys, was observed. The PEG-CBS treatment prevented an otherwise fatal liver disease characterized by steatosis, death of hepatocytes, and ultrastructural abnormalities of endoplasmic reticulum and mitochondria. Furthermore, treatment of the KO mice for 5 mo maintained the plasma metabolite balance and completely prevented osteoporosis and changes in body composition that characterize both the KO model and human patients. These findings argue that early treatment of patients with HCU with PEG-CBS may prevent clinical symptoms of the disease possibly without the need of dietary protein restriction.-Majtan, T., Hůlková, H., Park, I., Krijt, J., Kožich, V., Bublil, E. M., Kraus, J. P. Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.
650    _2
$a zvířata $7 D000818
650    _2
$a složení těla $x účinky léků $7 D001823
650    _2
$a cystathionin-beta-synthasa $x genetika $x metabolismus $x terapeutické užití $7 D003541
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ztučnělá játra $x enzymologie $x prevence a kontrola $7 D005234
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a homocystinurie $x farmakoterapie $x enzymologie $x metabolismus $x patologie $7 D006712
650    _2
$a játra $x účinky léků $x enzymologie $x metabolismus $x patologie $7 D008099
650    _2
$a nemoci jater $x enzymologie $x prevence a kontrola $7 D008107
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a osteoporóza $x prevence a kontrola $7 D010024
650    _2
$a rekombinantní proteiny $x terapeutické užití $7 D011994
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hůlková, Helena $u Institute of Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic. Institute of Pathology, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic; and.
700    1_
$a Park, Insun $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
700    1_
$a Krijt, Jakub $u Institute of Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
700    1_
$a Kožich, Viktor $u Institute of Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
700    1_
$a Bublil, Erez M $u Orphan Technologies Limited, Rapperswil, Switzerland.
700    1_
$a Kraus, Jan P $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA; jan.kraus@ucdenver.edu.
773    0_
$w MED00001782 $t FASEB journal official publication of the Federation of American Societies for Experimental Biology $x 1530-6860 $g Roč. 31, č. 12 (2017), s. 5495-5506
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28821635 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518091106 $b ABA008
999    __
$a ok $b bmc $g 1300039 $s 1013255
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 31 $c 12 $d 5495-5506 $e 20170816 $i 1530-6860 $m The FASEB journal $n FASEB J $x MED00001782
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace